Table 2 Clinical features of patients in the validation experiments
Clinical features | IHC patients (n = 95) | ELISA patients (n = 68) |
|---|---|---|
Age (range, years) | 67 (26-81) | 61 (29-83) |
Gender (male/female) | 51/44 | 43/25 |
Site | ||
Ascending colon | 32 (33.7%) | 13 (19.1%) |
Descending colon | 1 (1%) | 4 (5.9%) |
Tranverse colon | 0 (0%) | 2 (2.9%) |
Sigmoid colon | 31 (32.6%) | 25 (36.8%) |
Rectum | 31 (32.6%) | 24 (35.3%) |
Stage of CRC at diagnosis | ||
Stage I | 1 (1%) | 3 (4.4%) |
Stage II | 14 (14.7%) | 8 (11.8%) |
Stage III | 34 (35.8%) | 14 (20.6%) |
Stage IV | 46 (48.4%) | 43 (63.2%) |
Differentiation | ||
Well | 5 (5.3%) | 3 (4.4%) |
Moderately | 67 (70.5%) | 39 (57.4%) |
Poorly | 19 (20%) | 15 (22%) |
Unknown | 4 (4.2%) | 11 (16.2%) |
Previous chemotherapy in Neoadjuvant/Adjuvant setting | ||
Yes | 33 (34.7%) | 20 (29.4%) |
No | 62 (65.3%) | 48 (70.6%) |
Chemotherapy for mCRC | ||
FOLFOX/FLOX | 35 (36.8%) | 26 (38.2%) |
FOLFIRI | 15 (15.8%) | 11 (16.2%) |
Xelox | 20 (21.1%) | 22 (32.4%) |
5FU/Xeloda | 25 (26.3%) | 9 (13.2%) |
Microsatellite instability | 7 (8%) | 2 (3%) |
Yes | 64 (67%) | 50 (73%) |
No | 24 (25%) | 16 (24%) |
Unknown | ||
Maintenance bevacizumab | ||
Yes | 38 (40%) | 25 (36.8%) |
No | 57 (60%) | 43 (63.2%) |
PFS, median (range, days) | 340 (34-1655) | 338 (43-1819) |
OS, median (range, days) | 784 (78-2110) | 653 (98-1819) |
Duration of bevacizumab, median, days (range) | 242 (12-1169) | 238 (12-1245) |